Brion Winston, MD
Cardiovascular Disease · Albany, NYNPI 1932201159
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 68.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2020 at $41,752 and has fallen 63.1% since, to $15,402 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 579 payments — averaging $181.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$72K
- Angiodynamics, Inc.$15K
- Edwards Lifesciences$11K
- Inari Medical, Inc.$3K
- Abbott$1K
- Novartis$653
- plus $2K from 23 others
What the payments were for
- Consulting fees$18,86618%
- Speaking & faculty fees$58,60056%
- Travel & lodging$17,31816%
- Food & beverage$10,40010%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 139 | $72,460 |
| Angiodynamics, Inc. | 9 | $15,167 |
| Edwards Lifesciences | 207 | $11,246 |
| Inari Medical, Inc. | 1 | $2,500 |
| Abbott | 45 | $1,122 |
| Novartis | 65 | $653 |
| Pfizer | 20 | $302 |
| Amgen | 17 | $283 |
| W. L. Gore & Associates, Inc. | 2 | $217 |
| Johnson & Johnson | 13 | $214 |
| E.r. Squibb & Sons, L.L.C. | 11 | $192 |
| Abiomed | 3 | $189 |
| Boehringer Ingelheim | 8 | $153 |
| Chiesi USA, Inc. | 12 | $142 |
| AstraZeneca | 5 | $80 |
| Cardiovascular Systems Inc. | 4 | $61 |
| Gilead | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| B. Braun Interventional Systems Inc. | 1 | $13 |
| Merck | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL HEART$36,002
- GENERAL - THERAPIES$24,152
- AlphaVac$14,896
- LOTUS EDGE$6,939
- SAPIEN 3 Ultra RESILIA$3,440
- SPECTRA WAVEWRITER$2,685
- CT THROMBECTOMY SYSTEM KIT$2,500
- FLOWTRIEVER CATHETER, S$2,500
- Edwards SAPIEN 3 Transcatheter Heart Valve$530
- INGEVITY MRI$218
- Mitra Clip system$206
- AngioVac$198
- PRECISION$178
- GORE CARDIOFORM Septal Occluder$138
How this compares
$105,285 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 293 | $400,764 |
| VyndaqelTafamidis Meglumine | 12 | $241,989 |
| EntrestoSacubitril/Valsartan | 109 | $173,188 |
| JardianceEmpagliflozin | 121 | $168,536 |
| XareltoRivaroxaban | 60 | $89,498 |
| Repatha SureclickEvolocumab | 67 | $57,752 |
| WegovySemaglutide | 23 | $42,831 |
| BrilintaTicagrelor | 23 | $29,191 |
| MounjaroTirzepatide | 27 | $28,119 |
| OzempicSemaglutide | 30 | $27,912 |
| FarxigaDapagliflozin Propanediol | 24 | $23,597 |
| Atorvastatin Calcium | 947 | $11,318 |
| Praluent PenAlirocumab | 17 | $10,512 |
| Ranolazine ErRanolazine | 86 | $8,516 |
| ClopidogrelClopidogrel Bisulfate | 527 | $6,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndaqel | $302 | $642,752305 claims |
| NovartisEntresto | $653 | $173,188109 claims |
| Boehringer IngelheimJardiance | $153 | $168,536121 claims |
| Johnson & JohnsonXarelto | $214 | $89,49860 claims |
| Novo NordiskWegovy, Ozempic | $20 | $70,74353 claims |
| AstraZenecaBrilinta, Farxiga | $80 | $52,78847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$1.8M
- Rizwan AlimohammadAlbany$349K
- Edward PhilbinAlbany$226K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.